AHA 2020: Sotagliflozin Demonstrates Benefits in Diabetic Patients With Acute Decompensated Heart Failure or Chronic Kidney Diseases
SOLOIST-WHF and SCORED trials demonstrate reductions in cardiovascular death or hospitalizations/urgent visits for heart failure
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.